Diabetes News

The FDA has granted clearance to allow two integrated continuous glucose monitoring sensors to be used with automated insulin delivery systems, according to an industry press release.

NEW ORLEANS — Eliminating monthly copays for 15 classes of common heart and diabetes medications did not improve clinical outcomes or reduce health care costs, despite a modest improvement in medication adherence, researchers reported.

The FDA has granted 510(k) clearance for the launch of an Android mobile app for a connected smart cap for insulin pens, according to an industry press release.

Adults with type 1 diabetes spent more time in range with empagliflozin 2.5 mg or 5 mg as an adjunctive therapy to hybrid closed-loop insulin therapy compared with placebo, according to a speaker.

Adults with diabetes with commercial health insurance who use insulin manufactured by Eli Lilly and Company will have out-of-pocket costs capped at $35 per month, according to a company press release.

A popular artificial sweetener, erythritol, was linked to worsened risks for heart attack and stroke, according to new research published in Nature Medicine.

More than 60% of adults with type 2 diabetes and nearly 80% of those with type 1 diabetes said they experience some form of diabetes-related social stigma, according to survey data.

Once-daily liraglutide 3 mg as an adjunctive to lifestyle intervention is associated with a reduction in body weight and HbA1c for adolescents with type 1 diabetes and obesity, according to a speaker.

Researchers estimated that more than 80% of adults in the United States meet the criteria for GLP-1 receptor agonists or SGLT2 inhibitors, but only about one in 10 used either medication from 2017 to 2020.

Children with type 1 diabetes who switched from a predictive low-glucose suspend system to automated insulin delivery had improvements in time in range at 1 month that were sustained at 3 months, according to a speaker.